Search

Your search keyword '"Oden, Neal L."' showing total 306 results
Start Over Author "Oden, Neal L."
306 results on '"Oden, Neal L."'

8. Reply

Author

Scott, Ingrid U., primary, Oden, Neal L., additional, VanVeldhuisen, Paul C., additional, Ip, Michael S., additional, and Blodi, Barbara A., additional

Published
2024
Full Text
View/download PDF

9. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.

Author

Korthuis, Philip T, Lum, Paula J, Vergara-Rodriguez, Pamela, Ahamad, Keith, Wood, Evan, Kunkel, Lynn E, Oden, Neal L, Lindblad, Robert, Sorensen, James L, Arenas, Virgilio, Ha, Doan, Mandler, Raul N, McCarty, Dennis, and CTN-0055 CHOICES Investigators

Subjects
CTN-0055 CHOICES Investigators, Humans, HIV Infections, Alcoholism, Opioid-Related Disorders, Naltrexone, Narcotic Antagonists, Delayed-Action Preparations, Treatment Outcome, Feasibility Studies, Pilot Projects, Middle Aged, British Columbia, Chicago, Female, Male, Alcohol, HIV, extended-release naltrexone, injection drug use, opioid-related disorders, randomized clinical trial, Comparative Effectiveness Research, Neurosciences, Behavioral and Social Science, Substance Abuse, HIV/AIDS, Clinical Research, Clinical Trials and Supportive Activities, Alcoholism, Alcohol Use and Health, Infectious Diseases, Brain Disorders, Health Services, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Medical and Health Sciences, Psychology and Cognitive Sciences
Abstract

Background and aimsHIV-infected people with substance use disorders are least likely to benefit from advances in HIV treatment. Integration of extended-release naltrexone (XR-NTX) into HIV clinics may increase engagement in the HIV care continuum by decreasing substance use. We aimed to compare (1) XR-NTX treatment initiation, (2) retention and (3) safety of XR-NTX versus treatment as usual (TAU) for treating opioid use disorder (OUD) and/or alcohol use disorder (AUD) in HIV clinics.DesignNon-blinded randomized trial of XR-NTX versus pharmacotherapy TAU.SettingHIV primary care clinics in Vancouver, BC, Canada and Chicago, IL, USA.ParticipantsFifty-one HIV-infected patients seeking treatment for OUD (n = 16), AUD (n = 27) or both OUD and AUD (n = 8).MeasurementsPrimary outcomes were XR-NTX initiation (receipt of first injection within 4 weeks of randomization) and retention at 16 weeks. Secondary outcomes generated point estimates for change in substance use, HIV viral suppression [HIV RNA polymerase chain reaction (pcr)

Published
2017

10. SCORE2 Report 2 Study Design and Baseline Characteristics

Author

Scott, Ingrid U, VanVeldhuisen, Paul C, Ip, Michael S, Blodi, Barbara A, Oden, Neal L, Figueroa, Maria, Dugel, Pravin U, and Group, SCORE2 Investigator

Subjects
Eye Disease and Disorders of Vision, Clinical Trials and Supportive Activities, Clinical Research, Cardiovascular, Eye, Metabolic and endocrine, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Bevacizumab, Female, Fluorescein Angiography, Humans, Intravitreal Injections, Macular Edema, Male, Middle Aged, Prospective Studies, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Retinal Vein Occlusion, Tomography, Optical Coherence, Visual Acuity, SCORE2 Investigator Group, Clinical Sciences, Opthalmology and Optometry, Public Health and Health Services, Ophthalmology & Optometry
Abstract

PurposeTo describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials.DesignPhase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).ParticipantsTotal of 362 participants: 307 with CRVO and 55 with HRVO.MethodsDemographic and study eye characteristics are summarized and compared between CRVO and HRVO study participants.Main outcome measuresBaseline ophthalmic characteristics, including visual acuity and retinal thickness, and medical history characteristics, including hypertension, diabetes mellitus, and coronary artery disease.ResultsThe mean age of participants was 69 years, 76% of participants were white, and 90% were non-Hispanic. There was a racial disparity with respect to disease type, with 38% of HRVO patients being black compared with 11% of CRVO patients (P value adjusted for multiple testing = 0.0001). This is similar to findings from the previous SCORE Study. Comorbidities included hypertension (77%), diabetes mellitus (31%), and coronary artery disease (15%). At baseline, mean visual acuity letter score was 50 (20/100) (range, 19-73 [20/400 to 20/40]), mean optical coherence tomography (OCT)-measured central subfield thickness was 678 μm (range, 300-1203 μm), and mean number of months from diagnosis of macular edema to randomization was 6 (range, 0-104 months). One hundred twenty (33%) SCORE2 participants had been treated previously with anti-vascular endothelial growth factor (anti-VEGF) therapy, with these participants having baseline visual acuity letter score and OCT-measured central subfield thickness similar to those without prior anti-VEGF treatment, but longer mean duration of macular edema before randomization (18 months vs. 1 month for those without prior anti-VEGF treatment; P < 0.0001).ConclusionsThe SCORE2 cohort is a heterogeneous population, including both CRVO and HRVO eyes and both treatment-naïve eyes and eyes treated previously with anti-VEGF, which will allow study results to have broad applicability to CRVO and HRVO patients receiving treatment for macular edema. Similarities of the baseline characteristics of the SCORE2 population to other CRVO trial cohorts will allow meaningful comparisons of outcome results across trials.

Published
2017

11. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum

Author

Parker, Victoria E. R., Keppler-Noreuil, Kim M., Faivre, Laurence, Luu, Maxime, Oden, Neal L., De Silva, Leena, Sapp, Julie C., Andrews, Katrina, Bardou, Marc, Chen, Kong Y., Darling, Thomas N., Gautier, Elodie, Goldspiel, Barry R., Hadj-Rabia, Smail, Harris, Julie, Kounidas, Georgios, Kumar, Parag, Lindhurst, Marjorie J., Loffroy, Romaric, Martin, Ludovic, Phan, Alice, Rother, Kristina I., Widemann, Brigitte C., Wolters, Pamela L., Coubes, Christine, Pinson, Lucile, Willems, Marjolaine, Vincent-Delorme, Catherine, PROMISE Working Group, Vabres, Pierre, Semple, Robert K., and Biesecker, Leslie G.

Published
2019
Full Text
View/download PDF

12. High Variation in Inner Retinal Reflectivity Predicts Poor Visual Outcome in Patients With Central Retinal Vein Occlusion: SCORE2 Report 21

Author

Mehta, Nitish, primary, Patil, Sachi, additional, Modi, Vikram, additional, Vardi, Rachel, additional, Liu, Kevin, additional, Singh, Rishi P., additional, Sarraf, David, additional, Oden, Neal L., additional, VanVeldhuisen, Paul C., additional, Scott, Ingrid U., additional, Ip, Michael S., additional, Blodi, Barbara A., additional, and Modi, Yasha, additional

Published
2023
Full Text
View/download PDF

22. Reply

Author

Keenan, Tiarnan D.L., primary, Oden, Neal L., additional, Agrón, Elvira, additional, Clemons, Traci E., additional, Henning, Alice, additional, Wong, Wai T., additional, and Chew, Emily Y., additional

Published
2022
Full Text
View/download PDF

35. Genetics and Language in European Populations

Author

Sokal, Robert R., Oden, Neal L., Legendre, Pierre, Fortin, Marie-Josee, Kim, Junhyong, Thomson, Barbara A., Vaudor, Alain, Harding, Rosalind M., and Barbujani, Guido

Published
1990

39. Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion

Author

Scott, Ingrid U., Oden, Neal L., VanVeldhuisen, Paul C., Ip, Michael S., and Blodi, Barbara A.

Subjects
Male, Angiogenesis Inhibitors, Macular Edema, Bevacizumab, Ophthalmology, Treatment Outcome, Intravitreal Injections, Retinal Vein Occlusion, Humans, Valsartan, Female, Tomography, Optical Coherence, Original Investigation, Aged
Abstract

IMPORTANCE: Intravitreal anti–vascular endothelial growth factor (VEGF) injections are commonly used to treat eyes with macular edema secondary to hemiretinal vein occlusion (HRVO) or central retinal vein occlusion (CRVO). Information on whether differences exist in outcomes after anti-VEGF therapy can help guide treatment for each of the different disease types. OBJECTIVE: To compare baseline characteristics, treatment burden, and outcomes of macular edema treatment in participants with HRVO with those of participants with CRVO. DESIGN, SETTING, AND PARTICIPANTS: This post hoc outcome analysis from the Study of Comparative Treatments for Retinal Vein Occlusion 2 randomized clinical trial included 362 participants with macular edema caused by HRVO or CRVO treated at 66 US sites. Randomization began in September 2014, and the last month 24 follow-up visit occurred in February 2018. Data were analyzed from April 2020 to May 2021. INTERVENTIONS: Eyes were initially randomized to 6 monthly intravitreal injections of aflibercept or bevacizumab and were treated according to protocol between months 6 to 12 depending on 6-month outcome. After month 12, patients were treated per investigator discretion and observed through month 60. MAIN OUTCOMES AND MEASURES: Mean visual acuity letter score (VALS). RESULTS: Of 362 included patients, 157 (43.4%) were female, and the mean (SD) age was 68.9 (12.0) years. Outcome data were analyzed up to month 24 owing to substantial missing data at later visits. A significantly greater proportion of participants with HRVO than those with CRVO were Black (37% vs 11%). Treatment rates between months 12 to 23 were 0.36 (95% CI, 0.32-0.40) injections per month for patients with CRVO and 0.28 (95% CI, 0.19-0.36) for patients with HRVO (P = .11). The mean VALS from months 1 to 24 of an HRVO study eye exceeded that of a CRVO study eye by 5.5 (95% CI, 1.5-9.5; P = .01), consistent with the magnitude of the VALS difference between eyes with CRVO and HRVO at baseline. Eyes with CRVO presented at baseline with more macular edema than eyes with HRVO (difference in central subfield thickness [CST], 86 μm; 95% CI, 48-124; P

Published
2022

42. SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials

Author

Hendrick, Andrew, primary, VanVeldhuisen, Paul C., additional, Scott, Ingrid U., additional, King, Jacquie, additional, Blodi, Barbara A., additional, Ip, Michael S., additional, Khurana, Rahul N., additional, and Oden, Neal L., additional

Published
2021
Full Text
View/download PDF

47. Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial

Author

Aref, Ahmad A., Scott, Ingrid U., VanVeldhuisen, Paul C., King, Jacquie, Ip, Michael S., Blodi, Barbara A., Oden, Neal L., and Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results